Method and device for detecting ammonia odors and helicobacter pylori urease infection

Information

  • Patent Grant
  • 7582485
  • Patent Number
    7,582,485
  • Date Filed
    Thursday, October 16, 2003
    21 years ago
  • Date Issued
    Tuesday, September 1, 2009
    15 years ago
Abstract
The invention provides a breath testing device which visually indicates the presence of ammonia in a patient's breath, in particular ammonia from helicobacter pylori urease infection. The breath testing device comprises a visual indicating agent which changes color in response to ammonia odors, such as 4,4′-bis(dimethylamino)-benzhydrol (Michler's hydrol or BDMB), pararosaniline base and alpha-naphtholbenzein. The indicating agent is applied to a substrate which is then inserted into a tube or straw, which can be attached to the inlet of a breath collection balloon. When the patient blows into the tube or straw, the indicating agent will change color if it detects levels of ammonia which are consistent with helicobacter pylori urease infection.
Description
BACKGROUND OF THE INVENTION

The present invention relates to a method and device for detecting ammonia odors and uses thereof, in particular for diagnosing helicobacter pylori urease infection.


It is estimated that almost 1 in 10 adults will develop a stomach ulcer at some time in their lives. The bacterium Helicobacter pylori (HP) is known to be the cause of most stomach ulcers and ulcers of the duodenum and, once detected, can be cured by treatment with antibiotics. H. pylori (HP) produces an active form of the urease enzyme, which hydrolyzes urea into ammonia and carbon dioxide. Since ammonia is the key component generated by urease-catalyzed hydrolysis of urea, it follows that the presence of this compound in a person's breath can be used to diagnose helicobacter pylori urease (HPU) infection.


However, there are not many systems to detect ammonia odors, and of those available, most require the use of expensive instrumentation and are complex in operation (and hence not suitable for use by untrained users).


In general, HPU infection is diagnosed by analyzing the difference of exhaled ammonia and/or CO2 levels from a patient before and after swallowing a dose of radioactive urea. The levels of ammonia in HPU infected persons are usually between 100 to 200 parts per million (ppm) after swallowing the urea, whereas the levels of ammonia in an uninfected person after having swallowed the urea are much the same as before taking the urea (<2 ppm).


The patient first drinks a solution of citric acid as a background test and two baseline expired breath samples are collected in Mylar breath collection balloons from Kimberly-Clark/Ballard Medical Devices of Draper, Utah. The patient then drinks a second solution containing citric acid and carbon-14 labeled urea, and another two expired breath samples are taken after 30 minutes. The samples of expired breath are then analyzed for carbon-14 labeled carbon dioxide. The test is considered positive for H. Pylori infection when the difference between the control breath and the labeled breath samples are greater than 3.5 parts per thousand. This test is both expensive and time consuming.


Therefore, there is a clear need for a simple, safe device which needs neither expensive instrument nor radioactive materials for detecting ammonia from HPU infection and other sources.


SUMMARY OF THE INVENTION

This invention describes a simple device for detecting ammonia odors using a visual indicating agent which changes color when ammonia is present in the breath of a user, in particular when the ammonia is present in the range of 20 to 500 parts per million (ppm), more preferably in the range of 50 to 400 ppm, and most preferably in the range of 75 to 300 ppm.


The indicating agent is also suitable for diagnosing helicobacter pylori urease (HPU) infection, which causes ammonia to be present in a patient with the infection. The development of potential stomach ulcers can thus be inhibited or the stomach ulcers can be treated at an early stage.


The visual indicating agent is typically a dye which is color sensitive to ammonia odors, such as 4,4′-bis(dimethylamino)-benzhydrol (BDMB or Michler's hydrol (MH)), a dye having a similar chemical structure to MH, a triamino-triphenyl-methanol dye such as pararosaniline base (PAB), alpha-naphtholbenzein or any other dye which has high sensitivity for ammonia. The dye may change color by fading to a lighter color, by deepening in color or by actually changing from one color to another.


The device includes a simple carrier portion defining a passage, such as a substantially transparent tube or straw, containing the visual indicating agent. While the invention will be described hereinafter with particular reference to straws and tubes, it will be understood that the invention is useful with various other shapes as well. For example, the shape of the passageway may be cylindrical, triangular, square, almond-shaped and so forth.


The visual indicating agent may be in the form of a powder, in solution (for example, in water, an aqueous solution, toluene or alcohol), or may be coated onto a substrate, such as cellulose tissue or paper, a nonwoven fabric substrate, a woven substrate, glass fiber, cotton, silk, rayon and so forth. The solution may be applied to the substrate and dried so that a dry residue of the indicating agent remains on the substrate. The straw may be substantially flattened to allow for easier storage, while still permitting a patient to blow through the passage in the tube. The device may include a zone with one or more reference colors to allow the user to compare the color of the indicating agent after exposure to his or her breath with the reference color, and so easily determine if there has been a color change.


In one embodiment, the visual indicating agent is coated onto a cellulose substrate which is then inserted into a straw. In another embodiment, the visual indicating agent is again coated onto a cellulose susbstrate, but is placed over one end of a straw.


In both embodiments, when the patient blows into the tube, their breath will pass through the tube and over or through the substrate, thus causing the indicating agent to change color if levels of ammonia which are indicative of HPU infection (generally between 20 and 500 ppm) are present in the patient's breath.


The breath testing devices may be single-use devices which are disposable.


Thus, HPU infection can be detected by a simple color change, and there is no need for radioactive urea and complex instrumentation. No similar system has yet been developed or reported in the literature.


The straw may be connected to the inlet of a breath collection balloon such as the type sold commercially by Kimberly-Clark/Ballard Medical Devices of Draper, Utah for use in the existing H. pylori detection kits (PYtest™ 14C-Urea Breath Test). The use of such a balloon would help ensure that the correct amount of breath was sampled, as the patient would simply blow through the straw into the balloon until it was fully inflated.


The patient may ingest urea prior to his or her breath being tested so as to boost the ammonia levels which are detected. After a period of time sufficient to allow HPU, if present, to hydrolyze the urea into ammonia and carbon dioxide, the patient would then blow into a breath testing device. If the patient were infected with HPU, sufficient amounts of ammonia would be present in his or her breath to be detected by the device, and the indicating agent would show a change in color.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows a standard curve for the detection of ammonia by Michler's Hydrol-dye;



FIG. 2 shows a standard curve for the detection of ammonia by pararosaniline base (PAB);



FIG. 3 shows the results of a test to monitor the hydrolysis of urea to ammonia and carbon dioxide using PAB;



FIG. 4 shows simple breath testing device according to a first embodiment of the invention in an unassembled state, demonstrating a color change in the indicating agent before (left) and after (right) exposure to ammonia odors;



FIG. 5 shows a second embodiment of a breath testing device according to the invention with a color reference, before (right) and after (left) exposure to ammonia odors;



FIG. 6 shows a third embodiment of the breath testing device according to the invention;



FIG. 7 shows a fourth embodiment of the breath testing device according to the invention;



FIG. 8 shows the breath testing device of FIG. 4 in conjunction with a breath collection balloon.





DETAILED DESCRIPTION OF THE INVENTION

The invention provides simple breath testing devices which are able to detect levels of ammonia odors in a patient's breath which are consistent with helicobacter pylori urease infection without requiring the patient to ingest radio-active chemicals. Thus, the breath testing devices include a visual indicating agent which changes color in response to the ammonia odors, preferably when the ammonia is in the range of 20 to 500 parts per million (ppm), more preferably in the range of 50 to 400 ppm, and most preferably in the range of 75 to 300 ppm.


In one embodiment, the visual indicating agent is 4,4′-bis(dimethylamino)-benzhydrol, also known as “BDMD”, “Michler's hydrol” or “MH”. This indicating agent is sensitive to both sulphur-containing and amine-containing odors, changing from blue to colorless in the presence of these odors. Michler's Hydrol reacts with amine or sulfur compounds according to the following reaction:




embedded image


Michler—s hydrol (MH) and related indicating agents, which are also suitable for use as indicating agents for the present invention, can be represented by the following general formula (I) or (II):














embedded image
















Indicating Agent
R
R′
R″
Indicating Agent for





Michler's Hydrol
(CH3)2NC6H5
(CH3)2NC6H5
H
Ammonia, Amines,


(MH)



Diamines and Polyamines


Pararosaniline
(NH2)C6H5
(NH2)C6H5
(NH2)C6H5
Ammonia, Amines,


Base (PAB)



Diamines and Polyamines





Alpha- naphtholbenzein (ANB)
C6H5


embedded image




embedded image


Ammonia, Amines, Diamines and Polyamines





Naphthochrome Green (NCG)
C6H5


embedded image




embedded image


Ammonia, Amines, Diamines and Polyamines









The dye may change color by fading to a lighter color, by deepening in color or by actually changing from one color to another. Thus, MH changes from blue to colorless, PAB changes from red to colorless and ANB changes from yellow/orange to grey in the presence of ammonia.


The degree of the color change will depend on the concentration of the indicating agent or the concentration of ammonia in the patient's breath. Therefore, in order to observe a color change in response to ammonia levels in the range of 75 to 300 ppm, the concentration of indicating agent which is used is preferably in the range of from 0.01 to 15% wt/wt, more preferably from 0.05 to 2% wt/wt, and most preferably from 0.1 to 0.5% wt/wt.


In one embodiment, the visual indicating agent is coated onto a cellulose substrate which is then inserted into a straw. In another embodiment, the visual indicating agent is again coated onto a cellulose susbstrate, but is placed over one end of a straw.


The substrate, typically a cellulose tissue, may also be coated with nanoparticles to provide a high surface area coating on the substrate, i.e., higher than the cellulose fiber by itself. Thus, the cellulose tissue may be given a boost in surface area by coating it with nanoparticles. The treated substrate may be then coated with the visual indicating dye. It's believed that this high surface area coating helps spread the dye over the silica surface to provide a thinner coating and thus improving the sensitivity of the device.


The average size of the nanoparticles is generally less than about 100 nanometers, in fact it may be from about 1 to about 50 nanometers, and from about 4 to about 20 nanometers. As used herein, the average size of a particle refers to its average length, width, height, and/or diameter.


The nanoparticles may have a surface area of from about 50 square meters per gram (m2/g) to about 1000 m2/g, in some cases from about 100 m2/g to about 600 m2/g, and in some cases, from about 180 m2/g to about 240 m2/g.


In addition, the nanoparticles may also be relatively nonporous or solid. That is, the nanoparticles may have a pore volume that is less than about 0.5 milliliters per gram (ml/g), less than about 0.4 ml/gram, less than about 0.3 ml/g, and even from about 0.2 ml/g to about 0.3 mug. It is believed that the solid nature, i.e., low pore volume, of the nanoparticles may enhance the uniformity and stability of the nanoparticles.


Examples of commercially available alumina nanoparticles include, for instance, Aluminasol® 100, Aluminasol® 200 and Aluminasol® 520, which are available from Nissan Chemical America Corporation of Houston, Tex., USA. Alternatively, silica nanoparticles may be utilized, such as Snowtex-C®, Snowtex-O®, Snowtex-PS® and Snowtex-OXS® nanoparticles, which are also available from Nissan Chemical.


Snowtex-OXS® nanoparticles, for instance, have a particle size of from 4 to 6 nanometers, and may be ground into a powder having a surface area of approximately 509 square meters per gram. Also, alumina-coated silica particles may be used, such as Snowtex-AK® nanoparticles available from Nissan Chemical.


The breath testing device includes a simple supporting member, such as a substantially transparent tube or straw containing the visual indicating agent. The visual indicating agent may be in the form of a powder, in solution, or may be coated onto a substrate, such as cellulose tissue or paper, cotton, a non-woven fabric substrate, a woven substrate, glass fiber, silk, rayon and so forth. The indicating agent may also be printed onto the substrate, for example by using an inkjet printer.


The straw or tube may be substantially flattened to allow for easier storage, while still permitting a patient to blow through the passage in the tube.


The device may include a zone with one or more reference colors or shades of color to allow the user to compare the color of the indicating agent after exposure to his or her breath with the reference color, and so easily determine if there has been a color change.


In both embodiments, when the patient blows into the tube, their breath will pass through the tube and over or through the substrate, thus causing the indicating agent to change color if levels of ammonia which are indicative of HPU infection (generally from 20 to 500 ppm, more particularly from 50 to 400 ppm and most particularly between 75 to 300 ppm) are present in the patient's breath.


The straw or tube may be connected to the inlet of a breath collection balloon such as the type sold commercially by Kimberly-Clark/Ballard Medical Devices of Draper, Utah for use in the existing H. pylori detection kits (PYtest™ 14C-Urea Breath Test). Such a test balloon has a volume of about 0.5 to 2 liters or about 1 lung-full of breath for most individuals. The use of such a balloon helps ensure that the correct amount of breath is sampled. If too much breath is sampled, the device may provide a false positive diagnosis, and if too little breath is sampled, the device may provide a false negative diagnosis. Thus, the patient would simply blow through the straw into the balloon until it was fully inflated.


According to another embodiment, the breath testing devices described above were made smaller in size so that several of the breath testing devices could be easily packaged together in a pocket-sized container. For example, a straw was cut to about 4 cm in length, and a dye-treated substrate was either inserted into the straw or was placed over one end of the straw. The straw was then substantially flattened by laminating it in a standard business card heated laminator so that air was still able to pass through the tube of the straw.


The patient may ingest urea prior to his or her breath being tested so as to boost the ammonia levels which are detected. After a period of time sufficient to allow HPU, if present, to hydrolyze the urea into ammonia and carbon dioxide, the patient would then blow into the breath testing device. If the patient were infected with HPU, sufficient amounts of ammonia would be present in his or her breath to be detected by the device, and the indicating agent would show a change in color.


Unless otherwise specified, chemicals and biochemicals were obtained from Sigma-Aldrich of Milwaukee, Wis.


The most widely used color test is called CIELAB and is discussed in Pocket Guide to Digital Printing by F. Cost, Delmar Publishers, Albany, N.Y. ISBN 0-8273-7592-1 at pages 144 and 145. This method defines three variables, L*, a*, and b*, that correspond to three characteristics of perceived color based on the opponent theory of color perception. The three variables have the following meaning:


L*=Lightness, ranging from 0 to 100. Where 0=dark and 100=light,


a*=Red/green axis, ranging approximately from −100 to 100. Positive values are reddish and negative values are greenish.


b*=Yellow/blue axis, Ranging approximately from −100 to 100. Positive values are yellowish and negative values are blueish.


Because CIELAB color space is somewhat uniform, a single number can be calculated that represents the difference between two colors as perceived by a human being. This difference is termed ΔE and is calculated by taking the square root of the sum of the squares of the three differences (ΔL*, Δa*, and Δb*) between the two colors. In CIELAB color space, each ΔE unit is roughly a just-noticeable difference between two colors. So that the two colors have a difference of, for example, 4.4, the human eye can perceive the difference in color between the two colors. CIELAB is therefore a good measure for an objective device-independent color specification system that can be used as a reference color space for the purpose of color management and expression of changes in color.


Color intensities (L*a*b* values) herein were measured using a handheld spectrophotometer from Minolta Co. Ltd. of Osaka, Japan (Model # CM2600d). This instrument utilizes the D/8 geometry conforming to CIE No. 15, ISO 7724/1, ASTM E1164 and JIS Z8722-1982 (diffused illumination/8 degree viewing system. The D65 light reflected by the specimen surface at an angle of 8 degrees to the normal of the surface is received by the specimen-measuring optical system.


Absorbance readings were measured using a microplate reader from Dynex Technologies of Chantilly, Va. (Model # MRX).


An acetate buffer containing 40 mM sodium acetate and 4 M guanidine HCl, pH 5.1, was used for preparations of the indicating agents.


Paper towels or KIMWIPES® tissues from Kimberly-Clark Corporation of Neenah, Wis., were coated with Snowtex-O® nanoparticles (pH 4.1), available from Nissan Chemical and were used in the examples described herein with Michler's hydrol dye (MH or BDMB) or pararosaniline base (PAB), where dye was added without acetate buffer, unless otherwise indicated.


The invention will now be described in more detail by way of the following non-limiting examples.


EXAMPLE 1

A reaction mixture was placed into each of 8 vials containing 50 μl of ammonia hydroxide solution as an ammonia source (0, 0.01, 0.02, 0.04, 0.08, 0.16 and 0.64% of ammonia hydroxide, respectively) and 150 μl of MH dye (20 μl of 10.0 mg/ml MH in CH3CN with 5.0 ml of 40 mM sodium acetate and 4M guanidine HCl, pH5.1). After incubation of all the vials at room temperature for less than 4 minutes, a 200 μl portion from each vial was transferred to a microtiter plate well, and the absorbances were measured at 590 nm using a microtiter plate reader (The absorbances can also be measured in the range of 580-615 nm).


As shown in FIG. 1, a standard curve was derived by plotting the absorbance readings against the concentrations (ppb) of ammonia solutions. In FIG. 1, the x-axis is the concentration of ammonia in parts per billion (ppb) from 10 to 400 and the y-axis is the absorbance at 590 nm from 1 to 0.7. The sensitivity of ammonia detection by MH was shown to be very high.


EXAMPLE 2

A similar study was carried out with another dye, pararosaniline base (PAB), which was shown to be sensitive to amine and ammonia odors. In order to generate a standard curve (FIG. 2), a reaction mixture was placed into each of 8 vials containing 50 μl of an ammonia hydroxide solution as an ammonia source (0, 0.01, 0.02, 0.04, 0.08, 0.16 and 0.64% of ammonia hydroxide, respectively) and 150 μl of PAB solution (10 μl of 10 mg/ml PAB stock solution made in CH3CN with 5.0 ml of 40 mM sodium acetate and 4 M guanidine HCl, pH5.1). 200 μl of each reaction mixture was transferred to a mictotiter plate well and the wells were incubated at room temperature for 4 to 5 min. The absorbances were then read at 550 nm using a microplate reader. PAB was shown to be highly selective for ammonia and amine odors. In FIG. 2, the x-axis is the concentration of ammonia in parts per billion (ppb) from 10 to 400 and the y-axis is the absorbance at 550 nm from 1 to 1.0.


EXAMPLE 3

PAB was then used to see if it was suitable for use in monitoring the reaction in which urease catalyzes urea to ammonia and carbon dioxide by-products (FIG. 3). Into each of two vials (expt. 1 and expt. 2) was placed 1 ml of a reaction mixture containing 100 μl of 10 mM urea, 850 μl of 10 mM PBS, pH7.3, and 50 μl of 10.0 mg/ml urease. Three control vials were prepared, the first control excluding both urea and urease (control 1), the second control excluding urease but containing urea (control 2), and the third control excluding urea but containing urease (control 3). The vials were vortexed and 50 μl from each vial was transferred to a microtiter plate well. PAB solution (10 μl of 10 mg/ml PAB stock solution made in CH3CN with 5.0 ml of 40 mM sodium acetate and 4 M guanidine HCl, pH5.1) was then added to each well and the absorbance change with time was monitored at 550 nm using a microplate reader. In FIG. 3, the x-axis is time in minutes and the y-axis is the absorbance at 590 nm from 1 to 1.0. As can be seen in FIG. 3, the three controls had relative constant absorbance over time while the two experimental samples had falling absorbance over time. The PAB did not show any interference with buffer, urea, or urease alone, and was shown to be sensitive for ammonia generated by the urease reaction with urea.


EXAMPLE 4

A first embodiment of a device 10 for detecting HPU infection was designed using an ammonia-odor sensitive dye coated on a cellulose substrate (FIG. 4). Accordingly, 1 mg/ml stock solution of MH-dye was applied onto a SCOTT® paper towel from Scott Paper of Mississauga, ON, Canada, that had been previously coated with a 1 weight percent (dry) solution of SNOWTEX-O® nanoparticles and allowed to air dry. The dye-coated paper towel was then cut into 2 cm×4 cm strips 12 which were rolled up and each strip 12 was inserted into a clear plastic drinking straw 14 from Glad Products Company of Oakland, Calif.


The devices were tested by injecting known concentrations of ammonia hydroxide into the straws to determine their sensitivity to ammonia odors. A color change (from blue 16 to colorless 18) was noticed and was clearly visible in the presence of ammonia odors.


The experiment was repeated using PAB-dye and alpha-naphtholbenzein dye instead of MH-dye. On exposure to ammonia odors, the dye-coated substrates were observed to change from red to colorless and from yellow/orange to grey, respectively.


The color intensities (La*b*) of the indicating dye showed a clear difference between before and after the exposure to ammonia odors (˜100 ppb). The level of detection of ammonia odor by either MH or PAB (−100 ppb) is far less compared to the physiological level generated from urea hydrolysis by HP urease, Vmax, 1,100±200 μmol of urea hydrolyzed/min/mg of protein.


Several volunteers who had already been diagnosed with HPU infection were also given a number of these straws and were asked to blow into them with one lung-full of breath. A color change of the indicating dye on the substrate within the tubes was easily observed with the unaided eye.


EXAMPLE 5

As an alternative to coating a solution of the indicating agent onto a cellulose substrate as described in example 4 above, a solution of the indicating agent was formulated into an inkjet printable ink. Inkjet printing deposits a thin coating of dye on top of the substrate, potentially allowing a more sensitive color coating on the substrate. The Michler's Hydrol dye solution was formulated with inkjet additives shown in Table 1 below.









TABLE 1







Inkjet formulation








INK COMPONENT
VOLUME (ml)











Water (deionized)
0.85


Ethylene Glycol
3.0


Glycerol
1.5


Polyethylene Glycol (200 MW)
3.0


1,3-Propanediol
1.5


Michler's Hydrol (1.5 mg/ml) in 40 mM sodium acetate
40.1


and 4 M guanidine HCl, pH 5.1


TOTAL
50









The ink solution was loaded into empty Margarita® cartridges (part no. 0900400-300) obtained from McDermid-Colorspan of Eden Prairie, Minn. and printed using a wide format McDermid-Colorspan printer (Model XII). A strip of the printed Scott® paper towel was then exposed to ammonia odor and the blue color was observed to decolorize in about 10 seconds (compared to 3-5 minutes taken to observe the color change of a Scott® paper towel saturated with MH according to one of the previous examples). Higher sensitivity to the odor was thus observed by inkjet printing the indicating agent onto the substrate.


EXAMPLE 6

KIMWIPES® tissues were coated with a 5% Snowtex-O® nanoparticle solution from Nissan Chemical and then air-dried. 5.0 mg/ml stock solution of MH-dye in acetonitrile was applied to the Snowtex-O nanoparticle-coated KIMWIPES® tissues and a blue color was observed to develop as the applied dye solution dried.


As shown in FIG. 5, a drinking straw 20 from Glad Products Company of Oakland, Calif., was placed on a cardboard strip 22, and a piece of the dye-nanoparticle coated tissue 24 was placed over a first end 25 of the straw. Thus, when a patient breathes into the second end 26 of the straw, their breath would pass through the tissue 24 at the first end of the straw. The straw was placed between two sheets of polyethylene 28 which were then heat-sealed so that only the second end 26 of the straw was exposed. A reference (or control) color strip 30 was also placed between the polyethylene sheets near, but separate from, the first end 25 of the straw and sealed when the polyethylene sheets were heat sealed. This reference strip consists of a piece of the dye-coated tissue and allows the patient to compare the color of the strip 24 at the end of the drinking straw with the reference strip 30 to see if there has been a color change (left), and hence to determine whether he or she has HPU infection. The reference strip could also consist of a scale of two or more shades of blue so that the user could compare the change of color of the tissue in the straw with the scale, and so determine the degree of infection. For example, a slight change in the color could represent mild infection, a more pronounced fade to a lighter blue could represent medium infection, and a complete change from blue to colorless could represent severe infection.


EXAMPLE 7

The devices described in examples 4 and 6 were reduced in size to make them more discreet and easy to carry around.


Two minitiarized breath testing devices were therefore developed:


a) The first prototype (FIG. 7) was prepared by taking the article of example 4 (i.e. a drinking straw 40 into which a dye-treated tissue 42 had been inserted) and making the tube of the drinking straw shorter, for example, 4 cm long. The straw was then placed into a standard business card heated laminator (from Kinko's of Dallas, Tex.) so that the tube was flattened but air was still able to pass through the tube.

    • b) The second prototype (FIG. 6) was prepared by taking the article of example 6 (i.e. a drinking straw 44 having a dye-treated tissue strip 46 covering one end of the straw), and again cutting it to a length of approximately 4 cm. The straw was laminated as above.


EXAMPLE 8

In order to ensure that the HPU testing devices as described above would detect the levels of ammonia which are exhaled by patients having ulcers, it is preferable that a uniform amount of breath is sampled. Thus, the device described in example 4 was attached to a breath collection balloon 50 from Kimberly-Clark/Ballard Medical Devices of Draper, Utah (FIG. 8), discussed above. The patient would therefore blow through the device 10 into the balloon until the balloon becomes inflated, and if the substrate 12 with the indicating agent within the device 10 changed color after exposure to this amount of breath, this would indicate that the patient is suffering from HPU infection.


From the above examples, it can be seen that it is possible to detect HPU infection using a visual indicating agent which is sensitive to ammonia and/or amine odors, rather than requiring a patient to ingest radioactive materials and to use expensive and complex equipment.


While the invention has been described in detail with respect to specific embodiments thereof, it will be apparent to those skilled in the art that various alterations, modifications and other changes may be made to the invention without departing from the spirit and scope of the present invention. It is therefore intended that the claims cover or encompass all such modifications, alterations and/or changes.

Claims
  • 1. A kit for detecting Hellcobacter pylori, the kit comprising a breath testing device that contains a substrate on which a visual indicating agent is disposed that is color sensitive to ammonia at a concentration of about 20 to about 500 parts per million, wherein the substrate is located within a tubular carrier portion of a breath collecting device through which the breath of a user passes, wherein the visual indicating agent contains Michler's hydrol, and wherein the substrate further comprises nanoparticles having an average size of less than about 100 nanometers.
  • 2. The kit of claim 1, wherein the visual indicating agent is sensitive to ammonia at a concentration of about 50 to about 400 parts per million.
  • 3. The kit of claim 1, wherein the breath testing device comprises a reference zone.
  • 4. The kit of claim 1, wherein the nanoparticles have a surface area of from about 50 to about 1000 square meters per gram.
  • 5. The kit of claim 1, wherein the nanoparticles include silica, alumina, or combinations thereof.
  • 6. The kit of claim 1, wherein the substrate contains a fibrous material.
  • 7. The kit of claim 6, wherein the fibrous material contains cellulosic fibers.
  • 8. The kit of claim 1, wherein the carrier portion is open at least one end.
  • 9. The kit of claim 8, wherein the carrier portion is substantially flattened.
  • 10. The kit of claim 8, wherein the carrier portion is connected to a balloon.
  • 11. The kit of claim 1, wherein the substrate covers an end of a carrier portion of the breath collecting device.
  • 12. The kit of claim 1, wherein the visual indicating agent is applied to the substrate as a solution.
  • 13. The kit of claim 12, wherein the concentration of the visual indicating agent is from about 0.001 to about 15% wt/wt of the solution.
  • 14. The kit of claim 12, wherein the concentration of the visual indicating agent is from about 0.005 to about 2% wt/wt of the solution.
  • 15. The kit of claim 1, further comprising a source of urea, the urea being hydrolyzable in the presence of a urease enzyme to generate ammonia.
  • 16. The kit of claim 1, wherein the carrier portion is transparent.
US Referenced Citations (326)
Number Name Date Kind
2015864 Müller et al. Oct 1935 A
2429694 King Oct 1947 A
2534229 Carhart et. al. Dec 1950 A
2593146 Howard Apr 1952 A
3033655 Grosskopf May 1962 A
3193404 Davis Jul 1965 A
3266973 Crowley Aug 1966 A
3338992 Kinney Aug 1967 A
3341394 Kinney Sep 1967 A
3381688 Satas May 1968 A
3494821 Evans Feb 1970 A
3502538 Petersen Mar 1970 A
3502763 Hartmann Mar 1970 A
3507269 Berry Apr 1970 A
3542615 Dobo et al. Nov 1970 A
3615478 Hoshino et al. Oct 1971 A
3692618 Dorschner et al. Sep 1972 A
3794497 Pratt et al. Feb 1974 A
3802817 Matsuki et al. Apr 1974 A
3836633 Bescke Sep 1974 A
3842103 Smith Oct 1974 A
3849241 Butin et al. Nov 1974 A
3919437 Brown et al. Nov 1975 A
3960494 Verma et al. Jun 1976 A
3971665 Suzuki et al. Jul 1976 A
4006030 Yoshida et al. Feb 1977 A
4038101 Thompson Jul 1977 A
4041203 Brock et al. Aug 1977 A
4078029 Yoshida et al. Mar 1978 A
4100324 Anderson et al. Jul 1978 A
4101638 Inoue et al. Jul 1978 A
4144370 Boulton Mar 1979 A
4172781 Walk et al. Oct 1979 A
4243743 Hiramoto et al. Jan 1981 A
4297233 Gualandi Oct 1981 A
RE30797 Davis Nov 1981 E
RE30803 Davis Nov 1981 E
4313820 Farha, Jr. et al. Feb 1982 A
4340563 Appel et al. Jul 1982 A
4375448 Appel et al. Mar 1983 A
4407960 Tratnyek Oct 1983 A
4467012 Pedersen et al. Aug 1984 A
4469746 Weisman et al. Sep 1984 A
4488969 Hou Dec 1984 A
4494278 Kroyer et al. Jan 1985 A
4494629 Raeburn Jan 1985 A
4517308 Ehlenz et al. May 1985 A
4522203 Mays Jun 1985 A
4525410 Hagiwara et al. Jun 1985 A
4548906 Sekikawa et al. Oct 1985 A
4575556 Byrne et al. Mar 1986 A
4604313 McFarland et al. Aug 1986 A
4640810 Laursen et al. Feb 1987 A
4643801 Johnson Feb 1987 A
4655757 McFarland et al. Apr 1987 A
4670385 Babb et al. Jun 1987 A
4701218 Barker et al. Oct 1987 A
4715983 Ota et al. Dec 1987 A
4725415 Kidd Feb 1988 A
4734324 Hill Mar 1988 A
RE32649 Brandt et al. Apr 1988 E
4769216 Chandler et al. Sep 1988 A
4775585 Hagiwara et al. Oct 1988 A
4777018 Auchincloss Oct 1988 A
4780448 Broecker et al. Oct 1988 A
4781858 Mizukami et al. Nov 1988 A
4783220 Gamble et al. Nov 1988 A
4798603 Meyer et al. Jan 1989 A
4802473 Hubbard et al. Feb 1989 A
4804630 Bhattacharjee Feb 1989 A
4818464 Lau Apr 1989 A
4823404 Morell et al. Apr 1989 A
4823803 Nakamura Apr 1989 A
4844867 Bather Jul 1989 A
4853186 Mura et al. Aug 1989 A
4854332 Hanakura Aug 1989 A
4904304 Watanabe et al. Feb 1990 A
4947861 Hamilton Aug 1990 A
4969457 Hubbard et al. Nov 1990 A
4978615 Aoyama et al. Dec 1990 A
4988505 Watanabe et al. Jan 1991 A
5000746 Meiss Mar 1991 A
5020533 Hubbard et al. Jun 1991 A
5057302 Johnson et al. Oct 1991 A
5064473 Kubo et al. Nov 1991 A
5094962 Snyder et al. Mar 1992 A
5100581 Watanabe et al. Mar 1992 A
5100702 Maeda et al. Mar 1992 A
5108739 Kurihara et al. Apr 1992 A
5122418 Nakane et al. Jun 1992 A
5133803 Moffatt Jul 1992 A
5145518 Winnik et al. Sep 1992 A
5145727 Potts et al. Sep 1992 A
5169706 Collier, IV et al. Dec 1992 A
5174959 Kundu et al. Dec 1992 A
5178931 Perkins et al. Jan 1993 A
5183656 Uesaka et al. Feb 1993 A
5188885 Timmons et al. Feb 1993 A
5196177 Watanabe et al. Mar 1993 A
5204429 Kaminsky et al. Apr 1993 A
5209998 Kavassalis et al. May 1993 A
5220000 Theodoropulos Jun 1993 A
5221497 Watanabe et al. Jun 1993 A
5225374 Fare et al. Jul 1993 A
5230953 Tsugeno et al. Jul 1993 A
5238518 Okubi et al. Aug 1993 A
5245117 Withers et al. Sep 1993 A
5266289 Tsugeno et al. Nov 1993 A
5284703 Everhart et al. Feb 1994 A
5286624 Terashima et al. Feb 1994 A
5292868 Subramanian Mar 1994 A
5294717 Theodoropulos Mar 1994 A
5300365 Ogale Apr 1994 A
5322061 Brunson Jun 1994 A
5332432 Okubi et al. Jul 1994 A
5338713 Takagi et al. Aug 1994 A
5342876 Abe et al. Aug 1994 A
5350624 Georger et al. Sep 1994 A
5366947 Müller et al. Nov 1994 A
5382400 Pike et al. Jan 1995 A
5383450 Hubbard et al. Jan 1995 A
5397667 Law et al. Mar 1995 A
5407442 Karapasha Apr 1995 A
5407600 Ando et al. Apr 1995 A
5420016 Boguslaski et al. May 1995 A
5420090 Spencer et al. May 1995 A
5427844 Murai et al. Jun 1995 A
5429628 Trinh et al. Jul 1995 A
5432094 Delente Jul 1995 A
5451450 Erderly et al. Sep 1995 A
5458864 Tsugeno et al. Oct 1995 A
5472775 Obijeski et al. Dec 1995 A
5480636 Maruo et al. Jan 1996 A
5486356 Yim Jan 1996 A
5487938 Spencer et al. Jan 1996 A
5488126 Subramanian et al. Jan 1996 A
5527171 Soerensen Jun 1996 A
5529879 Hoshino et al. Jun 1996 A
5538548 Yamazaki Jul 1996 A
5539124 Etherton et al. Jul 1996 A
5540916 Parks Jul 1996 A
5547607 Ando et al. Aug 1996 A
5553608 Reese et al. Sep 1996 A
5554775 Krishnamurti et al. Sep 1996 A
5580655 El-Shall et al. Dec 1996 A
5583219 Subramanian et al. Dec 1996 A
5591797 Barthel et al. Jan 1997 A
5597512 Watanabe et al. Jan 1997 A
5661198 Inatani et al. Aug 1997 A
5663224 Emmons et al. Sep 1997 A
5679138 Bishop et al. Oct 1997 A
5679724 Sacripante et al. Oct 1997 A
5695868 McCormack Dec 1997 A
5733272 Brunner et al. Mar 1998 A
5773227 Kuhn et al. Jun 1998 A
5795985 Hüsler et al. Aug 1998 A
5813398 Baird et al. Sep 1998 A
5814370 Martino et al. Sep 1998 A
5817300 Cook et al. Oct 1998 A
5833952 Grigor et al. Nov 1998 A
5837352 English et al. Nov 1998 A
5843509 Calvo Salve et al. Dec 1998 A
5855788 Everhart et al. Jan 1999 A
5861144 Peterson et al. Jan 1999 A
5871872 Matijevic et al. Feb 1999 A
5874067 Lucas et al. Feb 1999 A
5880176 Kamoto et al. Mar 1999 A
5880309 Suzuki et al. Mar 1999 A
5882638 Dodd et al. Mar 1999 A
5885599 Peterson et al. Mar 1999 A
5897541 Uitenbroek et al. Apr 1999 A
5902226 Tasaki et al. May 1999 A
5905101 Fujiki et al. May 1999 A
5916596 Desai et al. Jun 1999 A
5948398 Hanamoto et al. Sep 1999 A
5948483 Kim et al. Sep 1999 A
5962566 Grandfils et al. Oct 1999 A
5964926 Cohen Oct 1999 A
5972389 Shell et al. Oct 1999 A
5985229 Yamada et al. Nov 1999 A
5989510 Abe et al. Nov 1999 A
5989515 Watanabe et al. Nov 1999 A
5989840 D'Angelo et al. Nov 1999 A
6004625 Ohshima Dec 1999 A
6007592 Kasai et al. Dec 1999 A
6024786 Gore Feb 2000 A
6039923 Klemm et al. Mar 2000 A
6045900 Haffner et al. Apr 2000 A
6047413 Welchel et al. Apr 2000 A
6057162 Rounbehler et al. May 2000 A
6060410 Gillberg-LaForce et al. May 2000 A
6073771 Pressley et al. Jun 2000 A
6075179 McCormack et al. Jun 2000 A
6096299 Guarracino et al. Aug 2000 A
6111163 McCormack et al. Aug 2000 A
6171811 Becerro De Bengoa Vallejo Jan 2001 B1
6172173 Spencer et al. Jan 2001 B1
6177608 Weinstrauch Jan 2001 B1
6190814 Law et al. Feb 2001 B1
6193844 McLaughlin et al. Feb 2001 B1
6225524 Guarracino et al. May 2001 B1
6228605 Marshall May 2001 B1
6238767 McCormack et al. May 2001 B1
6254894 Denkewicz, Jr. et al. Jul 2001 B1
6264615 Diamond et al. Jul 2001 B1
6277346 Murasawa et al. Aug 2001 B1
6277772 Gancet et al. Aug 2001 B1
6291535 Watanabe et al. Sep 2001 B1
6294222 Cohen et al. Sep 2001 B1
6299867 Aoyagi et al. Oct 2001 B1
6309736 McCormack et al. Oct 2001 B1
6312918 Ito et al. Nov 2001 B1
6315864 Anderson et al. Nov 2001 B2
6334988 Gallis et al. Jan 2002 B1
6344218 Dodd et al. Feb 2002 B1
6344272 Oldenburg et al. Feb 2002 B1
6358537 Hoshino et al. Mar 2002 B1
6358909 Ochomogo et al. Mar 2002 B1
6369290 Glaug et al. Apr 2002 B1
6376741 Guarracino et al. Apr 2002 B1
6387495 Reeves et al. May 2002 B1
6391262 Brinton et al. May 2002 B1
6398827 Ota et al. Jun 2002 B1
6406669 Duan et al. Jun 2002 B1
6410765 Wellinghoff et al. Jun 2002 B1
6416729 DeBerry et al. Jul 2002 B1
6425530 Coakley Jul 2002 B1
6427693 Blackstock et al. Aug 2002 B1
6428814 Bosch et al. Aug 2002 B1
6433243 Woltman et al. Aug 2002 B1
6440187 Kasai et al. Aug 2002 B1
6460989 Yano et al. Oct 2002 B1
6461735 Furuya et al. Oct 2002 B1
6467897 Wu et al. Oct 2002 B1
6468500 Sakaguchi et al. Oct 2002 B1
6475601 Sakaki et al. Nov 2002 B1
6479150 Liu et al. Nov 2002 B1
6479278 Marshall Nov 2002 B2
6491790 Proverb et al. Dec 2002 B1
6498000 Murasawa et al. Dec 2002 B2
6509169 Ratcliffe et al. Jan 2003 B2
6517199 Tomioka et al. Feb 2003 B1
6531704 Yadav et al. Mar 2003 B2
6533826 Gessner et al. Mar 2003 B1
6536890 Kato et al. Mar 2003 B1
6544492 DeBerry Apr 2003 B1
6548264 Tan et al. Apr 2003 B1
6551457 Westman et al. Apr 2003 B2
6562441 Maeda et al. May 2003 B1
6575383 Dobler et al. Jun 2003 B2
6578521 Raymond et al. Jun 2003 B2
6589562 Shefer et al. Jul 2003 B1
6589761 Freadman et al. Jul 2003 B1
6607711 Pedersen Aug 2003 B2
6617488 Springer et al. Sep 2003 B1
6623848 Brehm et al. Sep 2003 B2
6627377 Itatani et al. Sep 2003 B1
6638918 Davison et al. Oct 2003 B2
6639004 Falat et al. Oct 2003 B2
6645569 Cramer et al. Nov 2003 B2
6693071 Ghosh et al. Feb 2004 B2
6706537 Ignacio et al. Mar 2004 B2
6825040 Scaringe et al. Nov 2004 B2
6846956 Kast et al. Jan 2005 B2
6998250 McMichael et al. Feb 2006 B2
7014612 Hubbard et al. Mar 2006 B2
7022285 Arai et al. Apr 2006 B2
7052854 Melker et al. May 2006 B2
7101340 Braun Sep 2006 B1
7316899 McDevitt et al. Jan 2008 B2
7413550 MacDonald et al. Aug 2008 B2
20010000889 Yadav et al. May 2001 A1
20010023338 Guarracino et al. Sep 2001 A1
20010031248 Hall-Puzio et al. Oct 2001 A1
20010056246 Rodriguez-Fernandez et al. Dec 2001 A1
20020005145 Sherman Jan 2002 A1
20020066542 Jakob et al. Jun 2002 A1
20020068364 Arai et al. Jun 2002 A1
20020091071 Fischer et al. Jul 2002 A1
20020106466 Hausmann et al. Aug 2002 A1
20020110686 Dugan Aug 2002 A1
20020128336 Kolb et al. Sep 2002 A1
20020142937 Carter et al. Oct 2002 A1
20020149656 Nohr et al. Oct 2002 A1
20020150678 Cramer et al. Oct 2002 A1
20020176982 Rohrbaugh et al. Nov 2002 A1
20020177621 Hanada Nov 2002 A1
20020182102 Fontenot et al. Dec 2002 A1
20020182658 Polak et al. Dec 2002 A1
20030003589 Khalil et al. Jan 2003 A1
20030013369 Soane et al. Jan 2003 A1
20030021744 DeBerry et al. Jan 2003 A1
20030021983 Nohr et al. Jan 2003 A1
20030050211 Hage et al. Mar 2003 A1
20030056648 Fornai et al. Mar 2003 A1
20030070782 Proverb et al. Apr 2003 A1
20030082237 Cha et al. May 2003 A1
20030100842 Rosenberg et al. May 2003 A1
20030130631 Springer et al. Jul 2003 A1
20030147956 Shefer et al. Aug 2003 A1
20030147966 Franzen et al. Aug 2003 A1
20030181540 Quellet et al. Sep 2003 A1
20030203009 MacDonald Oct 2003 A1
20030203495 Rupp Oct 2003 A1
20030211618 Patel Nov 2003 A1
20030216660 Ben-Oren et al. Nov 2003 A1
20030235605 Lelah et al. Dec 2003 A1
20040033269 Hei et al. Feb 2004 A1
20040034157 Ghosh et al. Feb 2004 A1
20040043688 Soerens et al. Mar 2004 A1
20040077093 Pan Apr 2004 A1
20040122387 Long et al. Jun 2004 A1
20040175556 Clark et al. Sep 2004 A1
20040265742 Marck et al. Dec 2004 A1
20050012085 Lavi et al. Jan 2005 A1
20050037374 Melker et al. Feb 2005 A1
20050084977 Boga et al. Apr 2005 A1
20050085739 MacDonald et al. Apr 2005 A1
20050112085 MacDonald et al. May 2005 A1
20050124072 Boga et al. Jun 2005 A1
20050164320 McDevitt et al. Jul 2005 A1
20050186109 Nakamura et al. Aug 2005 A1
20050191704 Boga et al. Sep 2005 A1
20060003336 Song et al. Jan 2006 A1
20070249958 Martin et al. Oct 2007 A1
20080243015 MacDonald et al. Oct 2008 A1
Foreign Referenced Citations (67)
Number Date Country
0103214 Mar 1984 EP
0232141 Aug 1987 EP
0251783 Jan 1988 EP
0339461 Nov 1989 EP
0348978 Jan 1990 EP
0376448 Jul 1990 EP
0389015 Sep 1990 EP
0389023 Sep 1990 EP
0483500 May 1992 EP
0510619 Oct 1992 EP
0282287 Apr 1996 EP
0972563 Jan 2000 EP
0749295 Jul 2000 EP
1034800 Sep 2000 EP
001037045 Sep 2000 EP
1053788 Nov 2000 EP
1157672 Nov 2001 EP
1157672 Nov 2001 EP
001160569 Dec 2001 EP
1162172 Dec 2001 EP
1188854 Mar 2002 EP
1214878 Jun 2002 EP
1216675 Jun 2002 EP
1298071 Apr 2003 EP
1315526 Jun 2003 EP
62149322 Jul 1987 JP
3221142 Sep 1991 JP
92067913 Oct 1992 JP
WO 8902698 Apr 1989 WO
WO 9111977 Aug 1991 WO
WO 9112029 Aug 1991 WO
WO 9112030 Aug 1991 WO
WO 9619346 Jun 1996 WO
WO 9619346 Jun 1996 WO
WO 9705482 Feb 1997 WO
WO 9725076 Jul 1997 WO
9730351 Aug 1997 WO
WO 9820915 May 1998 WO
WO 9820915 May 1998 WO
WO 9826808 Jun 1998 WO
WO 9826808 Jun 1998 WO
WO 9826808 Jun 1998 WO
WO 9947252 Sep 1999 WO
WO 0003797 Jan 2000 WO
WO 0029036 Mar 2000 WO
WO 0029036 Mar 2000 WO
WO 00137764 Mar 2000 WO
0020852 Apr 2000 WO
WO 0059555 Oct 2000 WO
WO 0076558 Dec 2000 WO
WO 007658 Dec 2000 WO
WO 0106054 Jan 2001 WO
WO 0226272 Apr 2002 WO
WO 0249559 Jun 2002 WO
WO 0255115 Jul 2002 WO
WO 02062881 Aug 2002 WO
WO 02064877 Aug 2002 WO
WO 02083297 Oct 2002 WO
WO 02084017 Oct 2002 WO
WO 02095112 Nov 2002 WO
WO 02094329 Nov 2002 WO
WO 03000979 Jan 2003 WO
WO 03025067 Mar 2003 WO
WO 03032959 Apr 2003 WO
WO 03088931 Oct 2003 WO
WO 03092885 Nov 2003 WO
WO 2004000986 Dec 2003 WO
Related Publications (1)
Number Date Country
20050084977 A1 Apr 2005 US